Literature DB >> 2029783

Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid.

J Carlsson1, V W Armstrong, H Reiber, K Felgenhauer, D Seidel.   

Abstract

Apolipoprotein E was measured in paired sera and cerebrospinal fluid samples from 483 neurological patients. The average apolipoprotein E concentration was 7.5 (+/- 3.1) mg/l in cerebrospinal fluid and 93.5 (+/- 29.7) mg/l in serum. Mean apolipoprotein B concentrations in 88 patients were 0.77 +/- 3.4 mg/l in cerebrospinal fluid and 1.06 +/- 0.31 g/l in serum. The apolipoprotein E concentration in cerebrospinal fluid was much greater than expected for passive diffusion from serum. By contrast to apolipoprotein B, there was no correlation between the apolipoprotein E cerebrospinal fluid/serum concentration quotient and the albumin concentration quotient. This suggests that apolipoprotein E in cerebrospinal fluid, unlike apolipoprotein B, is locally synthesized and that the use of a cerebrospinal fluid/serum concentration quotient is unnecessary. In a control group (n = 64) the mean cerebrospinal fluid apolipoprotein E value (+/- SD) was 5.9 (1.6) mg/l. Elevated cerebrospinal fluid apolipoprotein E concentrations were observed in acute (n = 22, 12.5 +/- 6.2 mg/l) and chronic inflammatory central nervous system diseases (n = 15, 10.4 +/- 2.4 mg/l).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029783     DOI: 10.1016/0009-8981(91)90070-s

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  19 in total

1.  Measurement of apolipoprotein E (apoE) in cerebrospinal fluid.

Authors:  C Hesse; H Larsson; P Fredman; L Minthon; N Andreasen; P Davidsson; K Blennow
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

2.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

3.  Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?

Authors:  J-C Lambert; D Mann; F Richard; J Tian; J Shi; U Thaker; S Merrot; J Harris; B Frigard; T Iwatsubo; C Lendon; P Amouyel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

4.  Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta.

Authors:  Armando Sena; Klaus Bendtzen; Maria J Cascais; Rui Pedrosa; Véronique Ferret-Sena; Elisa Campos
Journal:  J Neurol       Date:  2010-06-04       Impact factor: 4.849

5.  Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

6.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

7.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

Authors:  T Wisniewski; E M Castaño; A Golabek; T Vogel; B Frangione
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

8.  Levels of apolipoprotein A-II in cerebrospinal fluid in patients with neuroborreliosis are associated with lipophagocytosis.

Authors:  L Táborský; P Adam; O Sobek; M Dostál; J Dvoráková; L Dubská
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

9.  Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides.

Authors:  Romain Simon; Marion Girod; Catherine Fonbonne; Arnaud Salvador; Yohann Clément; Pierre Lantéri; Philippe Amouyel; Jean Charles Lambert; Jérôme Lemoine
Journal:  Mol Cell Proteomics       Date:  2012-08-23       Impact factor: 5.911

10.  Apolipoprotein E: risk factor for Alzheimer disease.

Authors:  M S Tsai; E G Tangalos; R C Petersen; G E Smith; D J Schaid; E Kokmen; R J Ivnik; S N Thibodeau
Journal:  Am J Hum Genet       Date:  1994-04       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.